| Literature DB >> 19339180 |
Michael P Deninno1, Melissa Andrews, Andrew S Bell, Yue Chen, Cynthia Eller-Zarbo, Nan Eshelby, John B Etienne, Dianna E Moore, Michael J Palmer, Michael S Visser, Li J Yu, William J Zavadoski, E Michael Gibbs.
Abstract
Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19339180 DOI： 10.1016/j.bmcl.2009.03.024
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823